AbbVie Inc., which recently named a new CEO, and Tentarix Biotherapeutics have announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.   The collaboration will integrate AbbVie’s expertise in oncology and immunology with Tentarix’s proprietary Tentacles platform.   Tentacles are multi-functional, conditionally-active antibody-based biologics that are designed specifically...